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By virtue of its considerable genetic ver-
satility, Drosophilk melanogaster may be
used to detect, in the entire array of germ
cell stages, a wide spectrum of chemically
induced genetic alterations, including those
with severe or obvious effects, such as dom-
inant lethals, chromosome loss, complete and
mosaic translocations, recessive lethals, and
"visibles", and nondisjunction, as well as
those causing only mildly detrimental
effects but which in aggregate may be
as harmful as mutations with severe ef-
fects (1-3). Since the former are far more
readily detected than the latter, and include
the major types of genetic damage respon-
sible for abortions, diseases, abnormalities,
and malfunctionings in humans, they are as
a group, of obvious primary concern in any
mutagenicity testing program.
The two most widely used procedures used
in Drosophila screening for genetic altera-
tions in postmeiotic, meiotic, and premeio-
tic cells (and in existence now for more than
four decades) are the sex-linked recessive
lethal test and the translocation test, often
combined, in practice, in the same experi-
ment [see Abrahamson and Lewis (4) for
details of procedure]. The sex-linked reces-
sive lethal test detecting recessive mutations
(associated or not with chromosome aberra-
tions) arising in the X chromosome of male
germ line cells, is probably the most utili-
tarian in the battery of procedures available
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in Drosophila for mutagenicity testing. Rea-
sons are (a) scoring for lethals can be made
with relative ease and considerable preci-
sion, the precision increasing when putative
lethals undergo retesting, the latter itself a
relatively simple procedure; (b) whereas all
genes in the X chromosome may not give
rise to a lethal condition when hemizygous
for a "null" allele, by reducing this number
to as low as 20%o of the estimated 1000
genes in the X chromosome leaves some 200
to be tested, in the same experiment, for re-
cessive lethals [extrapolation to the figure
of 1000 genes derives most recently from the
work of Judd et al. (5); (c) the spontane-
ous rate of recessive lethals in the X chro-
mosome is relatively low (about 0.1-0.2%);
and (d) testing the X chromosome in the
male obviates the problem of pre-existing
lethals, since the male must be free of X
chromosome lethals to serve in the P1 gen-
eration. The translocation test, monitoring
the occurrence of interchanges between non-
homologous chromosomes in the male germ
line, is used as a means of determining the
potential of a chemical to induce chromo-
some breaks capable of rejoining and of be-
ing transmitted to the next generation as
balanced chromosome aberrations. The ra-
tionale for the choice of this test is based
on the following considerations. (a) Relative-
ly straightforward genetic procedures per-
mit detection of translocations between
chromosomes 2 and 3, between the Y
chromosome and chromosome 2, the Y
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locations involving all three chromosomes
simultaneously; thus a major portion of the
genome may be assayed for translocations
in the same experiment (only the X chro-
mosome and the small fourth chromosome
are not included in the testing). (b) The
spontaneous rate of translocations in Droso-
phila is very low, probably less than 10-4.
(c) Translocations arise only following chro-
mosome breakage, so that their recovery
provides unequivocal evidence of the break-
inducing ability of the chemical. Employ-
ment of a third procedure, one testing for
nondisjunction of chromosomes, a genetic
event of considerable importance in hu-
mans, which may be caused by nongenetic
factors (e.g. spindle failures, chromosome
stickiness) becomes particularly desirable
where the chemical under investigation fails
to show evidence of mutagenic activity as
judged by the results of the recessive
lethal and translocation tests. Whereas in
the past only nondisjunction of the X chro-
mosomes in the female or the X and Y
chromosomes in the male could be scored
with ease and precision, it is now relatively
simple to follow, by genetic means, nondis-
junction of the small fourth chromosome in
conjunction with nondisjunction of the sex
chromosomes (the former making use of the
special compound fourth chromosome). In
this way, events paralleling in principle those
leading to Turner's (XO) or Klinefelter's
(XXY) syndrome, and to group G-21 trisomy
(Down's syndrome) in humans may be mon-
itored in the same experiment.
Briefly, then, these procedures may be
used to detect three important classes of
genetic alterations: recessive lethals and
translocations representing transmissible al-
terations associated with both short-term
and long-term deleterious effects, and non-
disjunction leading to lethality of monosom-
ic and trisomic offspring or perhaps, of
greater significance to the health and econ-
omy of the population, to impairments in
surviving offspring. It should be noted, fur-
ther, that these type of genetic alterations
are either not testable or testable only with
considerable difficulty in germ cells of mam-
malian systems.
The question arises as to how these proce-
dures can most usefully be exploited in eval-
uating the potential mutagenic hazard of
a compound. Three ways may be described.
The simplest, although not always the most
informative, is to administer the compound
directly "off the shelf", by feeding, micro-
injection or by vacuum injection (6). How-
ever, under these circumstances, whereas
a positive response to the compound raises
the possibility that the compound may be
mutagenic in humans, a negative response
could be due to the absence in Drosophila
of the appropriate metabolic mechanism re-
quired to change the compound from a non-
mutagenic to a mutagenically active form.
To deal with this possible shortcoming, it
would be desirable to use Drosophila in
conjunction with experiments employing the
conventional mammalian host mediated as-
say or microsomal activating systems (7).
Thus, for each compound investigated,
results from the Drosophila tests and those
from the rodents would be evaluated, with
special attention given to a comparison of
the response of Drosophila to the compound,
and the in vitro and in vivo responses of
the indicator bacteria in the host mediated
assay. The desirability of subsequently us-
ing Drosophila as an indicator organism in
the host mediated assay to complement the
bacterial system woild be suggested if the
compound produces (a) no mutagenic effect
in Drosophila or in bacteria in vitro but a
positive effect in bacteria in vivo, or (b) a
mutagenic effect in Drosophila and in bac-
teria in vitro but not in bacteria in vivo.
The former suggests that the mammalian
host system causes an enhancing effect, the
latter suggests a detoxifying effect on the
mutagenic activity of the compound (8). It
should be noted that Lee et al. (9) and Gee
et al. (10), using blood plasma or other tis-
sues from mutagen-treated hamsters, and
Browning (11), using intraperitoneal fluid
from mice, have demonstrated the utiliza-
bility of Drosophila as an indicator organ-
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systems.
Finally, in view of the findings just noted,
it should not be long before Drosophila
(preferably in conjunction with the conven-
tional mouse host mediated assay or micro-
somal activating systems) is used to test
for the possible mutagenic action of com-
pounds found in humans, for example, thera-
peutic drugs, by assessing the mutation-
inducing ability of drug-containing body
fluids taken directly from the individuals re-
ceiving these drugs.
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